Paper19084938
Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan.
Kogure T and 17 others. World J Gastroenterol, 2008. Cited by 13 papers, by iCite.
Cite this record
ConductScience Library. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. Papers, record 19084938. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19084938
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Hepatitis C, Chronic | Major topic |
| Interferon-alpha | Major topic |
| Ribavirin | Major topic |
| Adult | |
| Aged | |
| Drug Therapy, Combination | |
| Female | |
| Genotype | |
| Hepacivirus | |
| Humans | |
| Interferon alpha-2 | |
| Japan | |
| Male | |
| Middle Aged | |
| Polyethylene Glycols | |
| RNA, Viral | |
| Recombinant Proteins | |
| Treatment Outcome | |
| Viral Load |
Source PubMed
References19
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15044832 | Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load. | Intervirology | 2004 | https://conductscience.org/library/papers/15044832 | PubMed |
| 2 | 15880320 | Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy. | Clin Gastroenterol Hepatol | 2005 | https://conductscience.org/library/papers/15880320 | PubMed |
| 3 | 17714473 | Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C. | Hepatol Res | 2008 | https://conductscience.org/library/papers/17714473 | PubMed |
| 4 | 15508082 | Hepatocellular carcinoma: recent trends in Japan. | Gastroenterology | 2004 | https://conductscience.org/library/papers/15508082 | PubMed |
| 5 | 12640530 | Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load. | J Gastroenterol | 2003 | https://conductscience.org/library/papers/12640530 | PubMed |
| 6 | 12395340 | Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. | Hepatology | 2002 | https://conductscience.org/library/papers/12395340 | PubMed |
| 7 | 12761728 | Side effects of therapy for chronic hepatitis C. | Gastroenterology | 2003 | https://conductscience.org/library/papers/12761728 | PubMed |
| 8 | 11583749 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. | Lancet | 2001 | https://conductscience.org/library/papers/11583749 | PubMed |
| 9 | 16871572 | Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. | Hepatology | 2006 | https://conductscience.org/library/papers/16871572 | PubMed |
| 10 | 17728547 | Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. | Intervirology | 2007 | https://conductscience.org/library/papers/17728547 | PubMed |
| 11 | 12360468 | Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. | Gastroenterology | 2002 | https://conductscience.org/library/papers/12360468 | PubMed |
| 12 | 17657816 | Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. | Hepatology | 2007 | https://conductscience.org/library/papers/17657816 | PubMed |
| 13 | 12195046 | Epidemiology and clinical aspects on hepatitis C. | Jpn J Infect Dis | 2002 | https://conductscience.org/library/papers/12195046 | PubMed |
| 14 | 12939591 | Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. | Hepatology | 2003 | https://conductscience.org/library/papers/12939591 | PubMed |
| 15 | 17854035 | Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. | J Med Virol | 2007 | https://conductscience.org/library/papers/17854035 | PubMed |
| 16 | 15057741 | Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. | Gastroenterology | 2004 | https://conductscience.org/library/papers/15057741 | PubMed |
| 17 | 15163776 | Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15163776 | PubMed |
| 18 | 9819446 | Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. | N Engl J Med | 1998 | https://conductscience.org/library/papers/9819446 | PubMed |
| 19 | 17877503 | Epidemiology of hepatocellular carcinoma in Japan. | Hepatol Res | 2007 | https://conductscience.org/library/papers/17877503 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 25755575 | Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India. | J Clin Exp Hepatol | 2014 | https://conductscience.org/library/papers/25755575 | PubMed |
| 24812506 | Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. | Int J Nanomedicine | 2014 | https://conductscience.org/library/papers/24812506 | PubMed |
| 23543311 | Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study. | J Gastroenterol | 2014 | https://conductscience.org/library/papers/23543311 | PubMed |
| 21706207 | Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C. | Dig Dis Sci | 2011 | https://conductscience.org/library/papers/21706207 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IFNA2 | 3440 | PubTator's text mining | https://conductscience.org/library/genes/3440 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19084938
GET https://conductscience.org/api/papers/v1/19084938/authors